Loading...
XNASCRDF
Market cap226mUSD
Jan 16, Last price  
3.40USD
1D
-1.16%
1Q
17.24%
Jan 2017
-86.51%
Name

Cardiff Oncology Inc

Chart & Performance

D1W1MN
XNAS:CRDF chart
P/E
—
P/S
463.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
80.53%
Rev. gr., 5y
5.24%
Revenues
488k
+26.42%
00650,000265,665257,696450,000259,246280,000313,000381,000505,000378,000245,000365,993359,000386,000488,000
Net income
-41m
L+10.49%
-5,371,027-7,844,326-2,480,000-5,449,138-2,239,212-11,566,000-11,810,938-14,325,000-27,471,000-39,204,000-24,907,000-16,461,000-16,152,000-19,279,947-27,742,000-37,506,000-41,441,000
CFO
-31m
L-8.67%
0-4,399,446-1,230,000-2,088,716-1,930,301-4,934,661-7,317,248-12,727,385-22,119,025-31,040,000-23,281,000-13,200,000-13,268,000-16,314,962-23,040,000-33,820,000-30,887,000
Earnings
Feb 26, 2025

Profile

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
URL
https://cardiffoncology.com/
IPO date
Jul 27, 2004
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
488
26.42%
386
7.52%
Cost of revenue
45,900
40,488
Unusual Expense (Income)
NOPBT
(45,412)
(40,102)
NOPBT Margin
Operating Taxes
(1,198)
Tax Rate
NOPAT
(45,412)
(38,904)
Net income
(41,441)
10.49%
(37,506)
35.20%
Dividends
(414)
Dividend yield
0.68%
Proceeds from repurchase of equity
75
BB yield
-0.12%
Debt
Debt current
1,382
675
Long-term debt
3,607
4,755
Deferred revenue
Other long-term liabilities
Net debt
(69,834)
(99,837)
Cash flow
Cash from operating activities
(30,887)
(33,820)
CAPEX
(582)
(892)
Cash from investing activities
36,195
38,149
Cash from financing activities
75
FCF
(44,838)
(39,246)
Balance
Cash
74,823
105,267
Long term investments
Excess cash
74,799
105,248
Stockholders' equity
(339,604)
(298,491)
Invested Capital
412,183
407,549
ROIC
ROCE
EV
Common stock shares outstanding
44,677
43,600
Price
1.48
5.71%
1.40
-76.71%
Market cap
66,122
8.33%
61,040
-73.98%
EV
(3,712)
(38,797)
EBITDA
(45,014)
(39,866)
EV/EBITDA
0.08
0.97
Interest
1,581
Interest/NOPBT